AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS
Clinical trials for AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS explained in plain language.
Never miss a new study
Get alerted when new AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS trials appear
Sign up with your email to follow new studies for AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare lung condition: inhaled protein therapy in trial
Disease control Recruiting nowThis study tests an inhaled drug called molgramostim in children aged 6 to 18 with autoimmune pulmonary alveolar proteinosis (aPAP), a rare disease where protein builds up in the lungs and makes breathing hard. All 5 participants will take the drug daily via a nebulizer for 12 mo…
Matched conditions: AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS
Phase: PHASE3 • Sponsor: Savara Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for rare lung disease: investigational drug now available through expanded access
Disease control AVAILABLEThis program offers adults with autoimmune pulmonary alveolar proteinosis (aPAP) access to an investigational inhaled medication called molgramostim. aPAP is a rare lung condition where surfactant builds up, making breathing difficult. The drug aims to help the lungs clear this b…
Matched conditions: AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS
Sponsor: Savara Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New national registry aims to unlock mysteries of rare lung disease
Knowledge-focused Recruiting nowThis study creates a national registry for people with pulmonary alveolar proteinosis (PAP), a rare lung condition. Researchers will collect data and blood samples to improve diagnosis, understand how the disease progresses, and develop better ways to measure its severity. Up to …
Matched conditions: AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC